Xuanzhu Biopharmaceutical Company Description

Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China.

Its lead product candidates includes Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

The company also develops KM501, a first-in-class HER2/HER2 bispecific antibody drug conjugate, which is in Phase I clinical trial; KM602, which is in Phase I clinical trial for anti-tumor; XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 inhibitor; and XZP-6924, a ubiquitin-specific protease 1 (USP1) inhibitor.

In addition, it develops XZB-0004, an oral small molecule anexelekto inhibitor; XZP-6877, a DNA-dependent protein kinase inhibitor; NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroid farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor.

The company was founded in 2008 and is headquartered in Beijing, China. Xuanzhu Biopharmaceutical Co., Ltd. is a former subsidiary of Sihuan Pharmaceutical Holdings Group Ltd.

Xuanzhu Biopharmaceutical Co., Ltd.

Country	China
Founded	2008
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	396
CEO	Jiakui Li

Contact Details

Address: 2107, Building 2 Beijing China
Website	xuanzhubio.com

Stock Details

Ticker Symbol	2575
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE1000074Q1
SIC Code	2836

Key Executives

Name	Position
Yanjun Xu	Executive Chairman of the Board
Dr. Jiakui Li	GM and Executive Director
Chengming He	Deputy GM and Board Secretary
Tung Ching Ng	Joint Company Secretary